Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination immunosuppressive therapy used for treating various autoimmune conditions. The combination includes: - **Azathioprine**: A purine analogue that hinders purine synthesis and becomes incorporated into DNA during the anabolic process, inhibiting lymphocyte proliferation. - **Rituximab**: A B-cell depleting anti-CD20 antibody that targets and eliminates B cells. - **Mycophenolate mofetil (MMF)**: Works by blocking the de novo synthesis of DNA, thereby inhibiting the proliferation of lymphocytes. - **Prednisone**: A corticosteroid that reduces inflammation and suppresses immune system activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azathioprine + rituximab + mycophenolate mofetil + prednisone.